Stockysis — AI-Powered Stock News & Sentiment Analysis

HC Wainwright & Co. Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $6

Benzinga Newsdesk www.benzinga.com Positive 82.0%

Neg 0% Neu 0% Pos 82%

HC Wainwright & Co. analyst Joseph Pantginis maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $4 to $6.

Comments

No comments yet. Be the first!